A new stance on CBD

The World Health Organization (WHO) announced months ago a different position on Cannabidiol   (CBD), one of the active cannabinoid chemicals in the marijuana plant. Research has shown CBD to have a range of properties that may be therapeutically useful. In 2018, an update critical review report (carried out by the Expert Committee of Drug Dependence) was released, and the next was stated:

“In humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD. At present, there are no case reports of abuse or dependence relating to the use of pure CBD. There are also no published statistics on non-medical use of pure CBD ”, said the organization.

Waiting for more research on CBD

The WHO also believes that there should be a different approach for this natural cannabinoid, with looser regulations and more research, so everyone can be correctly informed in this field.

On the same report, the toxic effects of CBD were extensively reviewed with a recent update of the literature, and in general, CBD has been found to have relatively low toxicity, no psychological effect and no affection on the embryonic development.

Benefits of CBD

About the therapeutic applications for CBD, the WHO recognizes a signal for transplant acceptance, and for reducing some of the symptoms of schizophrenia. Additionally, it also suggest it may be good to treat drug addictions, especially on opioid, cocaine, Tabaco and psychostimulant.

Finally, based on rigorous studies, the inform exposed the rest of the  benefits of cannabidiol as a medical drug for many diverse types of diseases, including hypoxia-isquemia, anti-asthmatic, anti-epileptic, antioxidant, anti-inflammatory, anti-tumor, anti-psychotic, anti-anxiety, analgesic and neuroprotective properties. Indeed, its powerful anti-seizure effect has been demonstrated in several publications, particularly in those cases with Dravet syndrome, Lennox-Gastaut syndrome[1] and refractory epilepsy.

Finally, cannabidiol may be useful for a number of other medical conditions. However, there is only pre-clinical and limited clinical studies. Therefore more investigation about CBD needs to be done.

Did you like the post? Give us some feedback! This post has been done based on existent research to the date of publication of the article. Due to the increase in studies based on medical cannabis, the information provided can vary over time and we’ll keep informing in further writings.

[1] Cannabidiol (CBD) Critical Review Report. Experti Committee on Drug Dependence. Fortieth Meeing. Geneva, 4-7 June 2018, World Health Organization


Leave a Reply